Remove Engineering Remove Metabolic Stability Remove Trials
article thumbnail

The Data-Driven Future of Drug Development

DrugBank

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

article thumbnail

Game-changing pan-TEAD inhibitor for solid tumours

Drug Target Review

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. The system optimised the molecules that were most likely to succeed in terms of potency, metabolic stability, synthetic accessibility, and more.

article thumbnail

Obstacles and innovations of macrocyclic drug development

Drug Target Review

Phase III trials for MK-0616 commenced in the second half of 2023. 11 Macrocycles can also be engineered in other ways to become more cell permeable; for example, by incorporating N-methyl groups in macrocyclic peptides. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. 8 Why are there not more macrocyclic drugs?